Notizie Newsletter
FDA Grants Capmatinib Breakthrough Designation in Frontline METex14-Mutated NSCLC
Sep 6, 2019 - The FDA has granted a breakthrough therapy designation to capmatinib (INC280) as a first-line treatment for patients with MET exon14 skipping (METex14)-mutated non-small cell lung cancer (NSCLC). The decision is based on primary findings from the phase II GEOMETRY ...Leggi tutto
USPSTF Releases Final Recommendation on Treatments for Reducing Breast Cancer Risk
Sep 4, 2019 - Risk-reducing therapies, such as tamoxifen, raloxifene, or aromatase inhibitors, should be administered to women who are at an increased risk for breast cancer and at a low risk for adverse events (AEs) associated with these medications, according to an updated ...Leggi tutto
ASTRO Guideline on Use of Radiation Therapy for Patients With Pancreatic Cancer
Sep 5, 2019 - A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients diagnosed with pancreatic cancer, including when radiation treatments are appropriate, as well as the ...Leggi tutto
ASCO and MASCC/ISOO Release a Clinical Practice Guideline on Medication-Related Osteonecrosis of the Jaw
Sep 5, 2019 - ASCO and the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) have published a clinical practice guideline on medication-related osteonecrosis of the jaw in the Journal of Clinical Oncology. The guideline ...Leggi tutto
Pembrolizumab/Axitinib Combo Approved in Europe for Frontline RCC
Sep 4, 2019 - The European Commission has approved the combination of pembrolizumab and axitinib for the frontline treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on findings from the phase III KEYNOTE-426 trial, in which the combination ...Leggi tutto